Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06651229CT.gov A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | — | Recruiting | — | — | — |
NCT06536959CT.gov VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | — | Recruiting | — | — | — |
NCT02829840CT.gov Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | — | Withdrawn | — | — | — |
NCT02489929CT.gov Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | — | Unknown | — | — | — |
NCT02204020CT.gov Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | — | Withdrawn | — | — | — |
NCT02497404CT.gov Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | — | Completed | — | — | — |
NCT02017457CT.gov Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | — | Completed | — | — | — |
NCT00946647CT.gov A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | — | Completed | — | — | — |
NCT00422890CT.gov Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | — | Completed | — | — | — |
NCT00339196CT.gov 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00915785CT.gov Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities | — | Completed | — | — | — |
NCT00382590CT.gov Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacytidine (this asset) | Janssen Research & Development, LLC | P3 | BB · 64 |
| Cyclophosphamide | Sawa Ito, MD | P4 | BB |
| Nivestim | City of Hope Medical Center | P4 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Daunomycin | OHSU Knight Cancer Institute | P3 | BB |
| Cytarabine | The First Affiliated Hospital of Soochow University | P4 | BB |
| Fludarabine | City of Hope Medical Center | P4 | BB |
| Idarubicin | OHSU Knight Cancer Institute | P4 | BB |
| Sitagliptin | Indiana University | P2 | BB |
+42 more in the Myelodysplastic Syndrome cohort
Other indications for Azacytidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P3 | B · 62 |
| Leukemia | — | P2 | B · 62 |
| Diffuse Large B-Cell Lymphoma | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacytidine in Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacytidine-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →